Study period | Pre-treatment | Treatment | Follow-up | |||
---|---|---|---|---|---|---|
Timepoint (weeks) | <− 2 | 0 | 6 | 12 | 24 | 36 |
Enrollment | ||||||
 Informed consent | X | |||||
 Eligibility assessment | X | |||||
 Baseline variables | X | |||||
 Allocation | X | |||||
Interventions | ||||||
 CCFES | ◊------ | ------------- | ------◊ | |||
 cNMES | ◊------ | ------------- | ------◊ | |||
 TOT | ◊------ | ------------- | ------◊ | |||
Assessments | ||||||
 End of Treatment Questionnaire | X | |||||
 SIS – Hand Section | X | X | X | |||
 Neuro-QOL UE Function | X | X | X | |||
 Modified Ashworth Scale | X | X | X | X | X | |
 UEFM | X | X | X | X | X | |
 BBT | X | X | X | X | X | |
 SULCS | X | X | X | X | X | |
 ARAT | X | X | X | X | X | |
 MEP excitability | X | X | X | |||
 Ipsilateral MEP excitability | X | X | X | |||
 Interhemispheric inhibition | X | X | X |